Literature DB >> 21917845

Expression and function of ErbB receptors and ligands in the pituitary.

Odelia Cooper1, George Vlotides, Hidenori Fukuoka, Mark I Greene, Shlomo Melmed.   

Abstract

The role of ErbB family in discreet pituitary functions is reviewed. Several ErbB receptor ligands, EGF, TGFα, and heregulin are differentially expressed in normal gonadotroph and lacto-somatotroph lineages, and other elements of the anterior pituitary. ErbB receptors, i.e. EGFR and ErbB2, are also localized to the anterior pituitary with preferential EGFR lactosomatotroph expression. EGF regulates CRH and ACTH secretion and corticotroph proliferation as well as exhibiting autocrine and paracrine effects on gonadotrophs and on lactosomatotroph proliferation, gene and protein expression, and hormonal secretion. EGF and EGFR are expressed in both functioning and non-functioning pituitary adenomas, with higher expression in more aggressive tumor subtypes. ErbB2 receptor is detected in all tumor subtypes, particularly in invasive tumors. ErbB tyrosine kinase inhibitors regulate hormonal secretion, cell morphology, and proliferation in lacto-somatotroph tumors, reflecting the emerging application of targeted pituitary therapeutics.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21917845      PMCID: PMC3758362          DOI: 10.1530/ERC-11-0066

Source DB:  PubMed          Journal:  Endocr Relat Cancer        ISSN: 1351-0088            Impact factor:   5.678


  95 in total

1.  Epidermal growth factor and gonadotropin-releasing hormone stimulate proliferation of enriched population of gonadotropes.

Authors:  G V Childs; G Unabia
Journal:  Endocrinology       Date:  2001-02       Impact factor: 4.736

2.  Sites of epidermal growth factor synthesis and action in the pituitary: paracrine and autocrine interactions.

Authors:  G V Childs; J Armstrong
Journal:  Clin Exp Pharmacol Physiol       Date:  2001-03       Impact factor: 2.557

3.  Cryptic gonadotropin-releasing hormone receptors of rat pituitary cells in culture are unmasked by epidermal growth factor.

Authors:  P Leblanc; A L'Héritier; C Kordon
Journal:  Endocrinology       Date:  1997-02       Impact factor: 4.736

4.  Hypothalamic astrocytes respond to transforming growth factor-alpha with the secretion of neuroactive substances that stimulate the release of luteinizing hormone-releasing hormone.

Authors:  Y J Ma; K Berg-von der Emde; F Rage; W C Wetsel; S R Ojeda
Journal:  Endocrinology       Date:  1997-01       Impact factor: 4.736

5.  Effect of mouse epidermal growth factor on plasma concentrations of LH, FSH and testosterone in rams.

Authors:  B W Brown; P E Mattner; B A Panaretto; G H Brown
Journal:  J Reprod Fertil       Date:  1989-11

Review 6.  Mechanisms for pituitary tumorigenesis: the plastic pituitary.

Authors:  Shlomo Melmed
Journal:  J Clin Invest       Date:  2003-12       Impact factor: 14.808

7.  Epidermal growth factor rapidly stimulates prolactin gene transcription.

Authors:  G H Murdoch; E Potter; A K Nicolaisen; R M Evans; M G Rosenfeld
Journal:  Nature       Date:  1982-11-11       Impact factor: 49.962

8.  Dependence of gonadotropin-releasing hormone-induced neuronal MAPK signaling on epidermal growth factor receptor transactivation.

Authors:  Bukhtiar H Shah; Jae-Won Soh; Kevin J Catt
Journal:  J Biol Chem       Date:  2002-11-21       Impact factor: 5.157

9.  Compromised reproductive function in adult female mice selectively expressing mutant ErbB-1 tyrosine kinase receptors in astroglia.

Authors:  Biao Li; Zhihui Yang; Jingwen Hou; April McCracken; M Anita Jennings; Mark Y J Ma
Journal:  Mol Endocrinol       Date:  2003-08-07

10.  Epidermal growth factor: a potential paracrine and autocrine system within the pituitary.

Authors:  A Mouihate; J Lestage
Journal:  Neuroreport       Date:  1995-07-10       Impact factor: 1.837

View more
  27 in total

Review 1.  Molecular basis of pharmacological therapy in Cushing's disease.

Authors:  Diego Ferone; Claudia Pivonello; Giovanni Vitale; Maria Chiara Zatelli; Annamaria Colao; Rosario Pivonello
Journal:  Endocrine       Date:  2013-11-23       Impact factor: 3.633

Review 2.  Pathogenesis of non-functioning pituitary adenomas.

Authors:  Maria Chiara Zatelli
Journal:  Pituitary       Date:  2018-04       Impact factor: 4.107

Review 3.  Role of tyrosine kinase inhibitors in the treatment of pituitary tumours: from bench to bedside.

Authors:  Anat Ben-Shlomo; Odelia Cooper
Journal:  Curr Opin Endocrinol Diabetes Obes       Date:  2017-08       Impact factor: 3.243

4.  Genomic analyses identify agents regulating somatotroph and lactotroph functions.

Authors:  Jun Fan; Cui Zhang; Qi Chen; Jin Zhou; Jean-Louis Franc; Qing Chen; Yunguang Tong
Journal:  Funct Integr Genomics       Date:  2016-10-05       Impact factor: 3.410

Review 5.  Genomics and Epigenomics of Pituitary Tumors: What Do Pathologists Need to Know?

Authors:  Sylvia L Asa; Ozgur Mete; Shereen Ezzat
Journal:  Endocr Pathol       Date:  2021-01-12       Impact factor: 3.943

6.  Expression of Eag1 K+ channel and ErbBs in human pituitary adenomas: cytoskeleton arrangement patterns in cultured cells.

Authors:  Margarita González del Pliego; Elsa Aguirre-Benítez; Karina Paisano-Cerón; Irene Valdovinos-Ramírez; Carlos Rangel-Morales; Verónica Rodríguez-Mata; Carmen Solano-Agama; Dolores Martín-Tapia; María Teresa de la Vega; Miguel Saldoval-Balanzario; Javier Camacho; María Eugenia Mendoza-Garrido
Journal:  Int J Clin Exp Pathol       Date:  2013-02-15

Review 7.  PI3K/Akt/mTOR and Raf/MEK/ERK signaling pathways perturbations in non-functioning pituitary adenomas.

Authors:  Hadara Rubinfeld; Ilan Shimon
Journal:  Endocrine       Date:  2012-05-03       Impact factor: 3.633

8.  ErbB receptor-driven prolactinomas respond to targeted lapatinib treatment in female transgenic mice.

Authors:  Xiaohai Liu; Maya Kano; Takako Araki; Odelia Cooper; Hidenori Fukuoka; Yukiko Tone; Masahide Tone; Shlomo Melmed
Journal:  Endocrinology       Date:  2015-01       Impact factor: 4.736

Review 9.  Familial isolated pituitary adenomas (FIPA) and the pituitary adenoma predisposition due to mutations in the aryl hydrocarbon receptor interacting protein (AIP) gene.

Authors:  Albert Beckers; Lauri A Aaltonen; Adrian F Daly; Auli Karhu
Journal:  Endocr Rev       Date:  2013-01-31       Impact factor: 19.871

10.  EGFR/ErbB2-Targeting Lapatinib Therapy for Aggressive Prolactinomas.

Authors:  Odelia Cooper; Vivien S Bonert; Jeremy Rudnick; Barry D Pressman; Janet Lo; Roberto Salvatori; Kevin C J Yuen; Maria Fleseriu; Shlomo Melmed
Journal:  J Clin Endocrinol Metab       Date:  2021-01-23       Impact factor: 5.958

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.